Sequenom Center for Molecular Medicine (doing business as Sequenom Laboratories), a wholly owned subsidiary of Sequenom, Inc., is a CAP-accredited and CLIA-certified molecular diagnostics laboratory. Sequenom holds or has access to intellectual property for noninvasive prenatal testing using circulating cell-free fetal nucleic acids. In the area of retinal care diagnostics, the company holds or has access to worldwide licenses to develop and commercialize diagnostic tests to predict genetic predisposition to late stage age-related macular degeneration (AMD).
Current Sequenom Laboratories tests include:
MaterniT21™ PLUS noninvasive prenatal test
The first commercial noninvasive prenatal test (NIPT) of its kind; detects fetal chromosomal abnormalities, including Down syndrome, as early as 10 weeks gestation.
SensiGene® Fetal RHD Genotyping noninvasive prenatal test
Detects fetal RHD genotype in RhD (-) mothers.
RetnaGene™ AMD noninvasive test
A test that evaluates the risk of early or intermediate AMD progressing to advanced choroidal neovascular disease with 2, 5 and 10 years.
The Heredi-T™ CF noninvasive carrier screen
Analyzes 136 mutations and 5 variants proven to be clinically relevant to cystic fibrosis.
NextView™ prenatal diagnostic tests
Offering the convenience of diagnostic testing that complement or follow NIPT.